PMID- 16954550
OWN - NLM
STAT- MEDLINE
DCOM- 20061024
LR  - 20191210
IS  - 0161-5505 (Print)
IS  - 0161-5505 (Linking)
VI  - 47
IP  - 9
DP  - 2006 Sep
TI  - Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 
      99mTc-NC100692.
PG  - 1434-9
AB  - The present study was a proof-of-concept study to provide an initial indication 
      of the efficacy and safety of imaging malignant breast tumors using 
      (99m)Tc-NC100692. The agent is a small peptide with high affinity for integrin 
      receptors that are upregulated and expressed preferentially on proliferating 
      endothelial cells. METHODS: Sixteen patients with suggestive mammographic 
      findings and 4 patients with benign lesions were included. The "standard of 
      truth" was based on the histopathologic diagnosis of the recruited patients. All 
      subjects received up to 75 microg of (99m)Tc-NC100692 with an average (99m)Tc 
      activity of 694 MBq (range, 561-747 MBq). Safety endpoints were 
      treatment-emergent adverse events (AEs) and changes in a limited physical 
      examination, electrocardiogram (ECG) recordings, blood biochemistry, hematology, 
      coagulation, vital signs, and urine analysis after administration of 
      (99m)Tc-NC100692 and throughout the 24-h follow-up. Static images and SPECT were 
      acquired between 40 min and 2.5 h after injection of the agent. Two experienced 
      nuclear medicine physicians read the images in a nonblinded fashion. RESULTS: 
      Nineteen of 22 malignant lesions were detected using (99m)Tc-NC100692 
      scintigraphy. Twenty lesions confirmed as malignant by histopathology were seen 
      on mammography or ultrasound. Two additional lesions were identified from 
      histopathology alone. Safety parameters evaluated through the follow-up period of 
      2.5 h included clinical laboratory tests, vital signs, and ECG. Five of 20 
      subjects experienced nonserious AEs, and all AEs were classified as mild. One 
      subject experienced an AE (dysgeusia) possibly related to administration of 
      (99m)Tc-NC100692. This AE was mild and lasted only for a few minutes. No deaths, 
      serious AEs, or withdrawals due to AEs occurred during the study. CONCLUSION: 
      Nineteen of 22 malignant lesions (86%) were clearly detected via scintigraphic 
      imaging after administration of (99m)Tc-NC100692. Overall, the efficacy data in 
      subjects with suspected breast lesions suggest that (99m)Tc-NC100692 scintigraphy 
      may be effective in detecting malignant lesions. The use of (99m)Tc-NC100692 in 
      subjects with breast cancer is safe and well tolerated. Further studies are 
      warranted to assess the clinical potential of (99m)Tc-NC100692.
FAU - Bach-Gansmo, Tore
AU  - Bach-Gansmo T
AD  - Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway. 
      tore.bach-gansmo@radiumhospitalet.no
FAU - Danielsson, Rimma
AU  - Danielsson R
FAU - Saracco, Ariel
AU  - Saracco A
FAU - Wilczek, Brigitte
AU  - Wilczek B
FAU - Bogsrud, Trond V
AU  - Bogsrud TV
FAU - Fangberget, Anne
AU  - Fangberget A
FAU - Tangerud, Ase
AU  - Tangerud A
FAU - Tobin, Derek
AU  - Tobin D
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Nucl Med
JT  - Journal of nuclear medicine : official publication, Society of Nuclear Medicine
JID - 0217410
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Integrin alphaVbeta3)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Organotechnetium Compounds)
RN  - 0 (Peptides, Cyclic)
RN  - 0 (Radiopharmaceuticals)
RN  - H0X34CV8RR (technetium 99m NC 100692)
SB  - IM
EIN - J Nucl Med. 2007 Apr;48(4):567
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/*metabolism
MH  - Breast Neoplasms/blood supply/*diagnostic imaging/*metabolism
MH  - Feasibility Studies
MH  - Female
MH  - Humans
MH  - Integrin alphaVbeta3/*metabolism
MH  - Middle Aged
MH  - Neoplasm Proteins/*metabolism
MH  - Neovascularization, Pathologic/diagnostic imaging/metabolism
MH  - Organotechnetium Compounds/*pharmacokinetics
MH  - Peptides, Cyclic/*pharmacokinetics
MH  - Pilot Projects
MH  - Radionuclide Imaging
MH  - Radiopharmaceuticals/pharmacokinetics
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
EDAT- 2006/09/07 09:00
MHDA- 2006/10/25 09:00
CRDT- 2006/09/07 09:00
PHST- 2006/09/07 09:00 [pubmed]
PHST- 2006/10/25 09:00 [medline]
PHST- 2006/09/07 09:00 [entrez]
AID - 47/9/1434 [pii]
PST - ppublish
SO  - J Nucl Med. 2006 Sep;47(9):1434-9.